NL7003022A - - Google Patents

Info

Publication number
NL7003022A
NL7003022A NL7003022A NL7003022A NL7003022A NL 7003022 A NL7003022 A NL 7003022A NL 7003022 A NL7003022 A NL 7003022A NL 7003022 A NL7003022 A NL 7003022A NL 7003022 A NL7003022 A NL 7003022A
Authority
NL
Netherlands
Application number
NL7003022A
Other versions
NL162904B (nl
NL162904C (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7003022A publication Critical patent/NL7003022A/xx
Publication of NL162904B publication Critical patent/NL162904B/xx
Application granted granted Critical
Publication of NL162904C publication Critical patent/NL162904C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL7003022.A 1969-03-10 1970-03-03 Werkwijze voor het bereiden van een n-carbamoyl- -10,11-dihydro-5h-dibenzo Ÿb,fŸ azepinederivaat met een anti-convulsieve werking, alsmede werkwijze voor het bereiden van farmaceutische preparaten met deze ver- binding. NL162904C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH358369A CH500196A (de) 1969-03-10 1969-03-10 Verfahren zur Herstellung von neuen Azepinderivaten

Publications (3)

Publication Number Publication Date
NL7003022A true NL7003022A (da) 1970-09-14
NL162904B NL162904B (nl) 1980-02-15
NL162904C NL162904C (nl) 1980-07-15

Family

ID=4259115

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7003022.A NL162904C (nl) 1969-03-10 1970-03-03 Werkwijze voor het bereiden van een n-carbamoyl- -10,11-dihydro-5h-dibenzo Ÿb,fŸ azepinederivaat met een anti-convulsieve werking, alsmede werkwijze voor het bereiden van farmaceutische preparaten met deze ver- binding.

Country Status (24)

Country Link
US (2) US3642775A (da)
AT (1) AT298492B (da)
BE (1) BE747085A (da)
BG (1) BG17576A3 (da)
BR (1) BR7017332D0 (da)
CA (1) CA920586A (da)
CH (1) CH500196A (da)
CS (1) CS154294B2 (da)
DE (1) DE2011087C3 (da)
DK (1) DK125649B (da)
ES (1) ES377279A1 (da)
FI (1) FI50523C (da)
FR (1) FR2034781B1 (da)
GB (1) GB1310571A (da)
HK (1) HK51976A (da)
IE (1) IE34046B1 (da)
IL (1) IL34026A (da)
KE (1) KE2635A (da)
MY (1) MY7600194A (da)
NL (1) NL162904C (da)
NO (1) NO130314B (da)
PL (1) PL80549B1 (da)
SE (1) SE349301B (da)
YU (1) YU33862B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
EP0108715A1 (de) * 1982-10-15 1984-05-16 Ciba-Geigy Ag Dibenzazepincarboxamide
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
IT1272897B (it) * 1995-01-13 1997-07-01 I F C Iniziative Finanziaarie Processo per la produzione di 10-oxo-10,11-diidro-sh- -dibenz(b,f) azepin-5-carbossiammide
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
DE59902734D1 (de) 1998-11-25 2002-10-24 Dsm Fine Chem Austria Gmbh Verfahren zur Oxidation von Methyl-, Methylen- oder Methingruppen enthaltenden Substraten
AT406957B (de) * 1998-11-25 2000-11-27 Dsm Fine Chem Austria Gmbh Verfahren zur oxidation von methyl-, methylen- oder methingruppen enthaltenden substraten
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
IT1317854B1 (it) * 2000-02-25 2003-07-15 Farchemia Srl 5-ciano-10-idrossi-10,11-diidro-5h-dibenz(b,f)azepina e procedimentiper la sua preparazione e per la sua conversione in
WO2002064557A2 (en) * 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
SG146631A1 (en) 2003-09-03 2008-10-30 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
WO2005066133A2 (en) * 2003-10-20 2005-07-21 Amoli Organics Ltd. NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE
ITMI20040452A1 (it) * 2004-03-09 2004-06-09 Clariant Lsm Italia Spa Processo per la preparazione di oxcarbazepina
US7459553B2 (en) * 2004-03-11 2008-12-02 Glenmark Generics Ltd. Process for the preparation of carboxamide compounds
WO2005096709A2 (en) * 2004-03-11 2005-10-20 Sun Pharmaceutical Industries Limited A process for the preparation of 10,11-dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide
EP1600443A1 (en) * 2004-05-26 2005-11-30 Alberto Milanese Process for the preparation of oxcarbazepine
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
ATE496623T1 (de) 2006-04-26 2011-02-15 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20090082335A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched oxcarbazepine
WO2009073154A1 (en) 2007-11-28 2009-06-11 Nektar Therapeutics Al, Corporation Oligomer-tricyclic conjugates
US8530647B2 (en) * 2008-05-08 2013-09-10 Mylan Laboratories Limited Process for the preparation of oxcarbazepine
WO2011091050A1 (en) 2010-01-19 2011-07-28 Nektar Therapeutics Oligomer-tricyclic conjugates
US20150232426A1 (en) 2012-09-26 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
PT3554490T (pt) 2016-12-16 2022-03-17 Idorsia Pharmaceuticals Ltd Combinação farmacêutica compreendendo um bloqueador de canais de cálcio de tipo t
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
MX2021003730A (es) 2018-09-28 2021-06-18 Univ Griffith Agentes y métodos para modular la actividad patógena.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH403767A (de) * 1961-06-09 1965-12-15 Geigy Ag J R Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen

Also Published As

Publication number Publication date
BE747085A (fr) 1970-09-09
HK51976A (en) 1976-08-27
NL162904B (nl) 1980-02-15
BR7017332D0 (pt) 1973-01-04
DK125649B (da) 1973-03-19
FI50523B (da) 1975-12-31
PL80549B1 (da) 1975-08-30
CS154294B2 (da) 1974-03-29
IL34026A (en) 1972-12-29
KE2635A (en) 1976-06-11
SE349301B (da) 1972-09-25
US3716640A (en) 1973-02-13
CA920586A (en) 1973-02-06
FR2034781B1 (da) 1973-04-06
BG17576A3 (bg) 1973-11-10
MY7600194A (en) 1976-12-31
GB1310571A (en) 1973-03-21
YU33862B (en) 1978-06-30
IE34046L (en) 1970-09-10
ES377279A1 (es) 1972-12-16
DE2011087C3 (de) 1979-08-30
NO130314B (da) 1974-08-12
IE34046B1 (en) 1975-01-08
IL34026A0 (en) 1970-05-21
FI50523C (fi) 1976-04-12
AT298492B (de) 1972-05-10
YU53670A (en) 1977-12-31
DE2011087A1 (de) 1970-09-24
NL162904C (nl) 1980-07-15
FR2034781A1 (da) 1970-12-18
CH500196A (de) 1970-12-15
US3642775A (en) 1972-02-15
DE2011087B2 (de) 1978-12-21

Similar Documents

Publication Publication Date Title
FR2034781B1 (da)
AU2270770A (da)
AU465413B2 (da)
AU4221168A (da)
AU2355770A (da)
AU442375B2 (da)
AU470301B1 (da)
AU5113869A (da)
CS151029B2 (da)
AT308690B (da)
AU414607B2 (da)
AU470661B1 (da)
AU417208B2 (da)
AU428129B2 (da)
AU442322B2 (da)
AU425297B2 (da)
AU410358B2 (da)
AU5133369A (da)
AU1036070A (da)
AU5077469A (da)
AR203167Q (da)
AU5079269A (da)
AU4923469A (da)
AU4953367A (da)
BE742216A (da)

Legal Events

Date Code Title Description
SNR Assignments of patents or rights arising from examined patent applications
V1 Lapsed because of non-payment of the annual fee